
FDA Accepts Outlook Therapeutics’ Biologics License Application for ONS-5010 in Wet AMD
The U.S. Food and Drug Administration (FDA) has accepted the resubmitted Biologics License Application (BLA) for ONS-5010 (bevacizumab-vikg) from Outlook Therapeutics, for the treatment of wet age-related macular degeneration (AMD). BLA Resubmission …